The biotech company reported $3.66 billion in net income for the quarter, a threefold increase over the $1.2 billion it reported in the same period last year.
With a market capitalization of nearly $72 billion, Boston-based Vertex Pharmaceuticals is one of the world's biggest biopharma businesses. Yet, there's an incredibly small chance that you or anyone you've ever encountered has ever been treated with any of its drugs.
Due to inadequate disclosure policies, drug company payments to European researchers and institutions for R&D work are often opaque, raising concerns about conflicts of interest and industry justifications for high medicine prices, according to a new study.